<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:02:08Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6735716" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6735716</identifier>
        <datestamp>2019-09-16</datestamp>
        <setSpec>rheumatology</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="letter">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="iso-abbrev">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="publisher-id">brheum</journal-id>
              <journal-title-group>
                <journal-title>Rheumatology (Oxford, England)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1462-0324</issn>
              <issn pub-type="epub">1462-0332</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6735716</article-id>
              <article-id pub-id-type="pmcid">PMC6735716</article-id>
              <article-id pub-id-type="pmc-uid">6735716</article-id>
              <article-id pub-id-type="pmid">31329965</article-id>
              <article-id pub-id-type="doi">10.1093/rheumatology/kez114</article-id>
              <article-id pub-id-type="publisher-id">kez114</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Letters to the Editor</subject>
                  <subj-group subj-group-type="category-toc-heading">
                    <subject>Others</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mortimer</surname>
                    <given-names>Isabel</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bissell</surname>
                    <given-names>Lesley-Anne</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5245-4755</contrib-id>
                  <name>
                    <surname>Hensor</surname>
                    <given-names>Elizabeth M. A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kozera</surname>
                    <given-names>Lukasz</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mackie</surname>
                    <given-names>Sarah L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3321-9087</contrib-id>
                  <name>
                    <surname>Burska</surname>
                    <given-names>Agata N.</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nam</surname>
                    <given-names>Jackie L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keen</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Villeneuve</surname>
                    <given-names>Edith</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Donica</surname>
                    <given-names>Helena</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buch</surname>
                    <given-names>Maya H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Conaghan</surname>
                    <given-names>Philip G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7429-8482</contrib-id>
                  <name>
                    <surname>Emery</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morgan</surname>
                    <given-names>Ann W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Andrews</surname>
                    <given-names>Jacqueline</given-names>
                  </name>
                  <xref ref-type="aff" rid="kez114-aff1">1</xref>
                  <xref ref-type="aff" rid="kez114-aff2">2</xref>
                  <xref ref-type="corresp" rid="kez114-cor1"/>
                  <!--<email>j.andrews@leeds.ac.uk</email>-->
                </contrib>
              </contrib-group>
              <aff id="kez114-aff1"><label>1</label>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds</aff>
              <aff id="kez114-aff2"><label>2</label>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK</aff>
              <aff id="kez114-aff3"><label>3</label>Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland</aff>
              <aff id="kez114-aff4"><label>4</label>Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK</aff>
              <author-notes>
                <corresp id="kez114-cor1">Correspondence to: Jacqueline Andrews, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: <email>j.andrews@leeds.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2019-04-16">
                <day>16</day>
                <month>4</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>16</day>
                <month>4</month>
                <year>2019</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>58</volume>
              <issue>9</issue>
              <fpage>1684</fpage>
              <lpage>1686</lpage>
              <history>
                <date date-type="accepted">
                  <day>26</day>
                  <month>2</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.</copyright-statement>
                <copyright-year>2019</copyright-year>
                <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="kez114.pdf"/>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">National Institute for Health Research</named-content>
                    <named-content content-type="funder-identifier">10.13039/501100000272</named-content>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">NIHR</named-content>
                    <named-content content-type="funder-identifier">10.13039/100006662</named-content>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">Leeds Biomedical Research Centre</named-content>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">NIHR Leeds Clinical Research Facility and Diagnostic Evaluation Co-operative</named-content>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">Merck Sharp &amp; Dohme</named-content>
                    <named-content content-type="funder-identifier">10.13039/100009947</named-content>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">National Health Service</named-content>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">NIHR</named-content>
                    <named-content content-type="funder-identifier">10.13039/100006662</named-content>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <named-content content-type="funder-name">Department of Health or Merck Sharp &amp; Dohme</named-content>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="3"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>
              <boxed-text id="kez114-BOX1" position="float" orientation="portrait">
                <sec>
                  <title>Rheumatology key message</title>
                  <p>
                    <list list-type="bullet">
                      <list-item>
                        <p>Initial treat-to-target therapy in early rheumatoid arthritis has sustained cardiovascular risk benefits at 4 years.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
            </p>
            <p><sc>Sir</sc>. It is well recognized that individuals with RA are at greater risk of cardiovascular disease (CVD), with EULAR guidance advising optimal control of disease activity to reduce this risk [<xref rid="kez114-B1" ref-type="bibr">1</xref>]. The cardiovascular substudy of the Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA) trial evaluated infliximab (IFX) + MTX <italic>vs</italic> MTX + methylprednisolone (MP) (<italic>n</italic> = 38 and 41 in each group, respectively) using a treat-to-target approach in early RA and reported improvements in soluble cardiovascular biomarkers in both groups at week 78, with a greater improvement in insulin resistance in the IFX + MTX group [<xref rid="kez114-B2" ref-type="bibr">2</xref>, <xref rid="kez114-B3" ref-type="bibr">3</xref>]. At week 78 the patients were discharged back to routine clinical care. Four years after their initial baseline IDEA visit, they were invited to participate in a follow-up study (IACON REC 09/H1307/98) to determine any long-term cardiovascular benefits of treat-to-target management and to evaluate for differences between the initial IFX + MTX and MTX + MP treatment arms.</p>
            <p>Following obtaining informed consent, patients were assessed for RA disease activity and medication use and any new diagnosis of ischaemic heart disease (IHD), cerebrovascular accidents (CVAs), peripheral arterial disease (PAD), hypertension, hypercholesterolaemia or diabetes mellitus (following medical notes review/patient questioning). Mirroring our previous IDEA substudy, blood samples were taken to quantify three commonly measured soluble cardiovascular biomarkers: N-terminal pro-brain natriuretic peptide (NT-proBNP), homeostasis model assessment–estimated insulin resistance (HOMA-IR) and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C).</p>
            <p>Eighteen patients were lost to follow-up between week 78 and year 4 (IFX + MTX, <italic>n</italic> = 10; MTX + MP, <italic>n</italic> = 8); follow-up data were available for 28 in the IFX + MTX group and 33 in the MTX + MP group. Comparing IFX + MTX <italic>vs</italic> MTX + MP at the baseline visit of the IDEA study, 64 <italic>vs</italic> 70% were female, 54 <italic>vs</italic> 64% were RF positive and 63 <italic>vs</italic> 78% were ACPA positive, respectively.</p>
            <p>At year 4, of those initially in the IFX + MTX group, the three-variable 28-joint DAS (DAS28) was 1.80 (95% CI 1.10, 2.50), none were receiving oral steroids, 75% were receiving conventional synthetic DMARDs (csDMARDs; 61% MTX monotherapy) alone and 25% were receiving biologic DMARDs [bDMARDs; 18% TNF inhibitor (TNFi) therapy; 12% IFX], compared with those initially in the MTX + MP group, where the three-variable DAS28 was 1.9 (95% CI 1.1, 2.35), 9% were receiving oral prednisolone (median dose 5 mg), 73% were receiving csDMARDs (36% MTX monotherapy) alone and 18% were receiving bDMARDs (15% TNFi therapy, 12% IFX).</p>
            <p>Since week 78, there were five new diagnoses of cardiovascular disease (IFX + MTX: 2 IHD, 1 CVA; MTX + MP: 1 IHD, 1 PAD), no new diagnoses of diabetes mellitus and seven new diagnoses of hypercholesterolaemia (IFX + MTX, <italic>n</italic> = 4; MTX + MP, <italic>n</italic> = 3). One (4%) of the IFX + MTX cohort received a new diagnosis of hypertension compared with six (18%) of the MTX + MP cohort (<italic>P</italic> = 0.225).</p>
            <p>Soluble biomarker data were available for 40 patients (IFX + MTX, <italic>n</italic> = 20; MTX + MP, <italic>n</italic> = 20). Results at weeks 26 and 78 were comparable to those of the original IDEA cardiovascular substudy [<xref rid="kez114-B2" ref-type="bibr">2</xref>]. Continued improvements in soluble biomarkers of cardiovascular risk 4 years from baseline were shown regardless of the drug regimen (see <xref rid="kez114-T1" ref-type="table">Table 1</xref>); NT-proBNP values were 53–69% of baseline, HOMA-IR were 45–57% of baseline and TC/HDL-C decreased by 1.28–1.61. There were no significant differences observed between the treatment groups at year 4.</p>
            <table-wrap id="kez114-T1" orientation="portrait" position="float">
              <label><sc>Table</sc> 1</label>
              <caption>
                <p>Changes to biomarker and lipoprotein values over time, separated by treatment regimen</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col valign="top" align="left" span="1"/>
                  <col valign="top" align="center" span="1"/>
                  <col valign="top" align="center" span="1"/>
                  <col valign="top" align="center" span="1"/>
                  <col valign="top" align="center" span="1"/>
                </colgroup>
                <thead align="left">
                  <tr>
                    <th rowspan="1" colspan="1">Change in variable</th>
                    <th rowspan="1" colspan="1">MTX + MP</th>
                    <th rowspan="1" colspan="1">IFX + MTX</th>
                    <th rowspan="1" colspan="1">Unadjusted difference (95% CI), <italic>P</italic>-value</th>
                    <th rowspan="1" colspan="1">Adjusted difference (95% CI), <italic>P</italic>-value<sup>b</sup></th>
                  </tr>
                </thead>
                <tbody align="left">
                  <tr>
                    <td colspan="5" rowspan="1">Week 26</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    NT-proBNP mean ratio</td>
                    <td rowspan="1" colspan="1">0.88 (n=30)</td>
                    <td rowspan="1" colspan="1">0.95 (n=26)(0.96)<sup>a</sup></td>
                    <td rowspan="1" colspan="1">1.09 (0.77, 1.54), 0.636<sup>c</sup>1.10 (0.77, 1.57), 0.610<sup>a,</sup><sup>c</sup></td>
                    <td rowspan="1" colspan="1">1.11 (0.78, 1.59), 0.548<sup>c</sup>1.14 (0.80, 1.61), 0.456<sup>a,</sup><sup>c</sup></td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    HOMA-IR mean ratio</td>
                    <td rowspan="1" colspan="1">0.67 (n=30)(0.74)<sup>a</sup></td>
                    <td rowspan="1" colspan="1">0.67 (n=25)</td>
                    <td rowspan="1" colspan="1">1.00 (0.57, 1.77), 0.990<sup>c</sup> 0.91 (0.53, 1.56), 0.725<sup>a,</sup><sup>c</sup></td>
                    <td rowspan="1" colspan="1">0.77 (0.50, 1.20), 0.244<sup>c</sup>0.74 (0.50, 1.11), 0.145<sup>a,</sup><sup>c</sup></td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    TC/HDL-C mean</td>
                    <td rowspan="1" colspan="1">−0.64 (n=30)</td>
                    <td rowspan="1" colspan="1">−0.82 (n=26)</td>
                    <td rowspan="1" colspan="1">−0.18 (−0.88, 0.52), 0.619</td>
                    <td rowspan="1" colspan="1">−0.21 (−0.78, 0.37), 0.472</td>
                  </tr>
                  <tr>
                    <td colspan="5" rowspan="1">Week 78</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    NT-proBNP mean ratio</td>
                    <td rowspan="1" colspan="1">0.79 (n=30)</td>
                    <td rowspan="1" colspan="1">0.91 (n=22)(0.91)<sup>a</sup></td>
                    <td rowspan="1" colspan="1">1.15 (0.75, 1.77), 0.517<sup>c</sup> 1.14 (0.74, 1.79), 0.529<sup>a,</sup><sup>c</sup></td>
                    <td rowspan="1" colspan="1">1.17 (0.76, 1.82), 0.473<sup>c</sup> 1.13 (0.75, 1.72), 0.550<sup>a,</sup><sup>c</sup></td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    HOMA-IR mean ratio</td>
                    <td rowspan="1" colspan="1">0.81 (n=30)(0.89)<sup>a</sup></td>
                    <td rowspan="1" colspan="1">0.66 (n=22)</td>
                    <td rowspan="1" colspan="1">0.81 (0.44, 1.51), 0.506<sup>c</sup> 0.74 (0.41, 1.33), 0.303<sup>a,</sup><sup>c</sup></td>
                    <td rowspan="1" colspan="1">0.64 (0.39, 1.06), 0.08<sup>c</sup> 0.62 (0.38, 0.098), 0.042<sup>a,</sup><sup>c</sup></td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    TC/HDL-C mean</td>
                    <td rowspan="1" colspan="1">−0.94 (n=29)</td>
                    <td rowspan="1" colspan="1">−1.13 (n=21)</td>
                    <td rowspan="1" colspan="1">−0.19 (−1.08, 0.69), 0.663</td>
                    <td rowspan="1" colspan="1">−0.12 (−0.75, 0.51), 0.701</td>
                  </tr>
                  <tr>
                    <td colspan="5" rowspan="1">Year 4</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    NT-proBNP mean ratio</td>
                    <td rowspan="1" colspan="1">0.53 (n=20)</td>
                    <td rowspan="1" colspan="1">0.69 (n=20)(0.69)<sup>a</sup></td>
                    <td rowspan="1" colspan="1">1.31 (0.74, 2.31), 0.342<sup>c</sup> 1.32 (0.73, 2.36), 0.346<sup>a,</sup><sup>c</sup></td>
                    <td rowspan="1" colspan="1">1.32 (0.73, 2.37), 0.350<sup>c</sup> 1. 31 (0.72, 2.38), 0.368<sup>a,</sup><sup>c</sup></td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    HOMA-IR mean ratio</td>
                    <td rowspan="1" colspan="1">0.45 (n=20)(0.52)<sup>a</sup></td>
                    <td rowspan="1" colspan="1">0.57 (n=20)</td>
                    <td rowspan="1" colspan="1">1.26 (0.67, 2.37), 0.471<sup>c</sup> 1.09 (0.61, 1.95), 0.765<sup>a,</sup><sup>c</sup></td>
                    <td rowspan="1" colspan="1">0.91 (0.58, 1.44), 0.679<sup>c</sup> 0.83 (0.59, 1.17), 0.272<sup>a,</sup><sup>c</sup></td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    TC/HDL-C mean</td>
                    <td rowspan="1" colspan="1">−1.28 (n=20)</td>
                    <td rowspan="1" colspan="1">−1.61 (n=20)</td>
                    <td rowspan="1" colspan="1">−0.33 (−1.45, 0.78), 0.551</td>
                    <td rowspan="1" colspan="1">−0.47(−1.061, 0.122), 0.116</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    HDL-C mean (<sc>s.d.</sc>), (mg/dl)</td>
                    <td rowspan="1" colspan="1">11.6 (14.0) (n=20)</td>
                    <td rowspan="1" colspan="1">18.0 (11.7) (n=20)</td>
                    <td rowspan="1" colspan="1">6.4 (−1.8, 14.7), 0.125</td>
                    <td rowspan="1" colspan="1">6.8 (−1.2, 14.7), 0.093</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    LDL-C mean (<sc>s.d.</sc>), (mg/dl)</td>
                    <td rowspan="1" colspan="1">22.2 (28.2) (n=20)</td>
                    <td rowspan="1" colspan="1">5.9 (41.5) (n=20)</td>
                    <td rowspan="1" colspan="1">−16.3 (−39.0, 6.4), 0.155</td>
                    <td rowspan="1" colspan="1">−12.3 (−31.0, 6.4), 0.190</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    ApoA mean (<sc>s.d.</sc>), (g/l)</td>
                    <td rowspan="1" colspan="1">−0.025 (0.365)(n=20)</td>
                    <td rowspan="1" colspan="1">−0.018 (0.192)(n=20)</td>
                    <td rowspan="1" colspan="1">0.007 (−0.180, 0.193), 0.944</td>
                    <td rowspan="1" colspan="1">0.032 (−0.131, 0.195), 0.694</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    ApoB mean (<sc>s.d.</sc>), (g/l)</td>
                    <td rowspan="1" colspan="1">0.255 (0.159)(n=20)</td>
                    <td rowspan="1" colspan="1">0.187 (0.251) (n=20)</td>
                    <td rowspan="1" colspan="1">−0.069 (−0.204, 0.067),0.310</td>
                    <td rowspan="1" colspan="1">−0.062 (−0.188, 0.063),0.320</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">    LpA, geometric mean, (g/l)</td>
                    <td rowspan="1" colspan="1">0.889 (n=16)</td>
                    <td rowspan="1" colspan="1">0.938 (n=15)</td>
                    <td rowspan="1" colspan="1">1.05 (0.72, 1.55), 0.777<sup>c</sup></td>
                    <td rowspan="1" colspan="1">1.03 (0.69, 1.53), 0.887<sup>c</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="tblfn1">
                  <label>a</label>
                  <p>Minus extreme outlier.</p>
                </fn>
                <fn id="tblfn2">
                  <label>b</label>
                  <p>Adjusted for baseline values.</p>
                </fn>
                <fn id="tblfn3">
                  <label>c</label>
                  <p>Values exponentiated to give the ratio of the difference of one group <italic>vs</italic> another with associated CIs.</p>
                </fn>
                <fn id="tblfn4">
                  <p>*<italic>P</italic> &lt; 0.05.</p>
                </fn>
                <fn id="tblfn5">
                  <p>ApoA: apolipoprotein A; ApoB: apolipoprotein B; LDL: low-density lipoprotein cholesterol; LpA: lipoprotein A.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>While the difference in the incidence of new hypertension did not reach statistical significance, and notably some patients in the MTX + MP group were taking oral prednisolone at year 4, it may be clinically important. While glucocorticoids have a known association with hypertensive disease [<xref rid="kez114-B4" ref-type="bibr">4</xref>], IFX has been linked with reduced systolic blood pressure in patients with RA. In a trial of 16 RA patients, new IFX exposure was associated with a reduction in systolic blood pressure, along with reductions in plasma norepinephrine and renin activity [<xref rid="kez114-B5" ref-type="bibr">5</xref>]. This could suggest that the mechanism extends beyond that of simply reducing disease activity and inflammation.</p>
            <p>Our cross-sectional analysis may also suggest that the initial beneficial impact of IFX + MTX on insulin resistance shown at week 78 had been lost by 4 years. However, the findings are limited by the small sample size and cross-sectional nature of the analysis, with a lack of knowledge about fluctuating disease activity/inflammation over the last 30 months—a known confounder of HOMA-IR [<xref rid="kez114-B6" ref-type="bibr">6</xref>]. In addition to patients receiving oral steroids at year 4 in the MTX + MP group, not all patients remained on IFX after week 78 in the alternative arm. Perhaps, for sustained insulin resistance improvement, continuous exposure to the drug is required.</p>
            <p>To conclude, we report an intensive 78 week treat-to-target programme in early RA is associated with sustained long-term benefit in the improvement of soluble biomarkers of CVD, suggesting the potential for a reduction of cardiovascular risk in the long term.</p>
            <p><italic>Funding</italic>: This study was funded internally and supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, NIHR Leeds Clinical Research Facility and Diagnostic Evaluation Co-operative and a research grant from the investigator-initiated studies program of Merck Sharp &amp; Dohme. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, the Department of Health or Merck Sharp &amp; Dohme.</p>
            <p><italic>Disclosure statement</italic>: P.G.C. has participated in speakers bureaus or consulted for AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer and Roche. M.H.B. has received research grant support and/or honoraria/consultancy fees from Pfizer, Roche-Chugai and UCB; has received honoraria/consultancy fees from AbbVie, Aurora, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Sandoz and Sanofi. P.E. has undertaken clinical trials and provided expert advice to Pfizer, Merck Sharp &amp; Dohme, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Samsung, Sandoz and Ely Lilly. E.V. has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen and UCB and research support from AbbVie. H.K. has received honoraria from Janssen and research support from Centocor and Schering-Plough. A.W.M. has received research grant support and/or honoraria/consultancy fees from Merck Sharp &amp; Dohme, Roche-Chugai, GlaxoSmithKline and Sanofi. L.A.B. has received honoraria from UCB. The other authors have declared no conflicts of interest.</p>
          </body>
          <back>
            <ref-list id="REF1">
              <title>References</title>
              <ref id="kez114-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agca</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Heslinga</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Rollefstad</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update</article-title>. <source>Ann Rheum Dis</source><year>2017</year>;<volume>76</volume>:<fpage>17</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">27697765</pub-id></mixed-citation>
              </ref>
              <ref id="kez114-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bissell</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Hensor</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Kozera</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study</article-title>. <source>Rheumatology</source><year>2016</year>;<volume>55</volume>:<fpage>2181</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">27638812</pub-id></mixed-citation>
              </ref>
              <ref id="kez114-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Villeneuve</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hensor</surname><given-names>EM</given-names></name><etal>et al</etal></person-group><article-title>Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)</article-title>. <source>Ann Rheum Dis</source><year>2014</year>;<volume>73</volume>:<fpage>75</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">23912798</pub-id></mixed-citation>
              </ref>
              <ref id="kez114-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Geller</surname><given-names>DS.</given-names></name></person-group><article-title>Glucocorticoid-induced hypertension</article-title>. <source>Pediatr Nephrol</source><year>2012</year>;<volume>27</volume>:<fpage>1059</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">21744056</pub-id></mixed-citation>
              </ref>
              <ref id="kez114-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Takeuchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kotani</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients</article-title>. <source>J Hum Hypertens</source><year>2014</year>;<volume>28</volume>:<fpage>165</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">24005958</pub-id></mixed-citation>
              </ref>
              <ref id="kez114-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoelson</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Goldfine</surname><given-names>AB.</given-names></name></person-group><article-title>Inflammation and insulin resistance</article-title>. <source>J Clin Investig</source><year>2006</year>;<volume>116</volume>:<fpage>1793</fpage>–<lpage>801</lpage>.<pub-id pub-id-type="pmid">16823477</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
